Andrew Craig Miller - 24 Feb 2026 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role: Director
Signature: /s/ Marc Grasso, as Attorney-in-Fact
Issuer symbol: KYTX
Transactions as of: 24 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Mar 2026, 16:30:04 UTC
Previous filing: 18 Mar 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Miller Andrew Craig	Director	C/O KYVERNA THERAPEUTICS, INC., 5980 HORTON ST., STE 550, EMERYVILLE	/s/ Marc Grasso, as Attorney-in-Fact	04 Mar 2026	0001777760

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYTX	Common Stock	Award		+11,006		$0.000000^*	11,006	24 Feb 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYTX	Stock Option (right to buy)	Award		+42,945		$0.000000^*	42,945	24 Feb 2026	Common Stock	42,945	$7.95	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit award of common stock and 1/3rd of the shares underlying the restricted stock unit award shall vest on each one-year anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2	1/36th of the shares subject to the option shall vest on each monthly anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.